Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Potential to become a new modality in the treatment of ulcerative colitis offering prolonged remission without immune suppression
-
The study which compared MB310, a precision microbiome medicine, with placebo in 29 ulcerative colitis (UC) patients met its primary and secondary objectives to demonstrate safety, efficacy and engraftment:
Efficacy: